The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA.

导出 OA

翻译打印收藏纠错

作者： Alina,Muenchow ^[1] ; Sandra,Weller ^[2] ; Clemens,Hinterleitner ^[3] ; Elke,Malenke ^[4] ; Stefanie,Bugl ^[3] ; Stefan,Wirths ^[3] ; Martin R,Müller ^[3] ; Klaus,Schulze-Osthoff ^[5] ; Walter E,Aulitzky ^[6] ; Hans-Georg,Kopp ^[7] ; Frank,Essmann ^[8]

作者单位： Department of Molecular Oncology, Robert Bosch Centre for Tumor Diseases and Robert-Bosch-Hospital, Auerbachstr. 110, 70376, Stuttgart, Germany. ^[1] Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstr. 112, 70376, Stuttgart, Germany. ^[2] Department of Internal Medicine II, University of Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany. ^[3] University Children's Hospital Tübingen, Hoppe-Seyler-Str. 1, 72076, Tübingen, Germany. ^[4] Department of Oncology, Hematology and Immunology, Klinikum Siloah, 30449, Hannover, Germany. ^[5] Department of Molecular Medicine, Interfaculty Institute for Biochemistry, University of Tübingen, Hoppe-Seyler-Str. 4, 72076, Tübingen, Germany. ^[6] German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. ^[7] Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch-Hospital, Auberbachstr. 110, 70376, Stuttgart, Germany. ^[8] Department of Molecular Oncology, Robert Bosch Centre for Tumor Diseases and Robert-Bosch-Hospital, Auerbachstr. 110, 70376, Stuttgart, Germany. hans-georg.kopp@rbk.de. ^[9] Department of Internal Medicine II, University of Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany. hans-georg.kopp@rbk.de. ^[10] Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstr. 112, 70376, Stuttgart, Germany. frank.essmann@ikp-stuttgart.de. ^[11]